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Rationale A number of randomized trials are underway, which will address the effects of angiotensin receptor blockers
(ARBs) on aortic root enlargement and a range of other end points in patients with Marfan syndrome. If individual participant
data from these trials were to be combined, a meta-analysis of the resulting data, totaling approximately 2,300 patients, would
allow estimation across a number of trials of the treatment effects both of ARB therapy and of β-blockade.
Such an analysis would also allow estimation of treatment effects in particular subgroups of patients on a range of end points of
interest and would allow a more powerful estimate of the effects of these treatments on a composite end point of several clinical
outcomes than would be available from any individual trial.
Design A prospective, collaborative meta-analysis based on individual patient data from all randomized trials in Marfan
syndrome of (i) ARBs versus placebo (or open-label control) and (ii) ARBs versus β-blockers will be performed.
A prospective study design, in which the principal hypotheses, trial eligibility criteria, analyses, and methods are specified in
advance of the unblinding of the component trials, will help to limit bias owing to data-dependent emphasis on the results of
From the aDivision of Cardiovascular Medicine, Radcliffe Department of Medicine,
University of Oxford, Oxford, UK, bClinical Trial Service Unit & Epidemiological Studies
Unit, University of Oxford, Oxford, UK, cChildren's Hospital Boston and Harvard Medical
School, Boston, MA, dNew England Research Institutes, Watertown, MA, eNational Heart,
Lung, and Blood Institute, NIH, Bethesda, MD, fUniversity of Texas Southwestern Medical
Center, Dallas, TX, gAcademic Medical Center, University of Amsterdam, Amsterdam, The
Netherlands, hCenter for Medical Genetics and Department of Cardiology, University
Hospital Ghent, Ghent, Belgium, iCenter for Medical Genetics, University Hospital Ghent,
Ghent, Belgium, jCentre for Inherited Cardiovascular Diseases, IRCCS Foundation, San
Matteo Hospital, Pavia, Italy, kClinical Trials and Evaluation Unit, Royal Brompton &
Harefield NHS Trust, London, UK, lJohn Radcliffe Hospital, Oxford, UK, mFaculty of
Medicine and Health Sciences, University of East Anglia, Norwich, UK, nUCL Institute of
Cardiovascular Science, The Heart Hospital, London, UK, oDepartment of Cardiac and
Vascular Sciences, St George's Hospital, University of London, London, UK, pHospital
Universitario 12 de Octubre, Madrid, Spain, qMarfan Sydrome Unit, Department of
Cardiology, Hospital Vall d'Hebron, Barcelona, Spain, rDepartment of Pediatrics and Adult
Congenital Heart Center, Taipei Medical University Hospital, Taipei, Taiwan, sDepartment
of Pediatrics and Adult Congenital Heart Center, National Taiwan University Hospital,
Taipei, Taiwan, tChildren's Heart Centre, British Columbia's Children's Hospital,
Vancouver, British Columbia, Canada, uMassachusetts General Hospital, Boston, MA,
vBrigham andWomen's Hospital andHarvardMedical School, Boston,MA,
w
Weill Cornell
Medical College and New York-Presbyterian Hospital, New York, NY, xCenter for Medical
Genetics, Faculty of Medicine and Health Sciences, University of Antwerp and Antwerp
University Hospital, Antwerp, Belgium,
y
Oxford Centre for Clinical Magnetic Resonance
Research, Division of Cardiovascular Medicine, Radcliffe Department of Medicine,
University of Oxford, Oxford, UK,
z
Radcliffe Department of Medicine, University of Oxford,
Oxford, UK,
aa
Inserm LVTS U1148, Departement de Génétique, Hôpital Xavier
Bichat-Claude Bernard, Paris, France,
ab
Centre National de Référence pour le syndrome
de Marfan et apparentés, INSERM LVTS U1148, Service de Cardiologie, AP-HP Hôpital
Bichat, Paris, France, and
ac
McKusick-Nathans Institute of GeneticMedicine, Johns Hopkins
University School of Medicine, and the Howard Hughes Medical Institute, Baltimore, MD.
Submitted July 27, 2014; accepted January 17, 2015.
Reprint requests: Alex Pitcher, BMBCh, Division of Cardiovascular Medicine, Radcliffe
Department of Medicine, University of Oxford, John Radcliffe Hospital, Headington,
Oxford, OX3 9DU, UK.
E-mail: alex.pitcher@cardiov.ox.ac.uk
0002-8703
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0).
http://dx.doi.org/10.1016/j.ahj.2015.01.011
particular trials. The use of individual patient data will allow for analysis of the effects of ARBs in particular patient subgroups
and for time-to-event analysis for clinical outcomes.
The meta-analysis protocol summarized in this report was written on behalf of the Marfan Treatment Trialists' Collaboration and
finalized in late 2012,without foreknowledge of the results of any component trial, andwill bemade available online (http://www.
ctsu.ox.ac.uk/research/meta-trials). (Am Heart J 2015;169:605-12.)
Background
Marfan syndrome is a heritable disorder of connective
tissue, which typically produces symptoms and physical
or imaging signs in several organ systems, with involve-
ment of the cardiovascular, ocular, and musculoskeletal
systems being particularly prominent.1-5 The most
clinically important feature for most patients is a very
high prevalence of aortic aneurysm formation (particu-
larly, but not exclusively, in the aortic root at the sinuses
of Valsalva), conferring a dramatically increased risk of
potentially life-threatening aortic dissection and rupture.6
The prevalence of Marfan syndrome (based on hospital
attendances) has recently been estimated at around 1 in
10,000 people,7 but the condition often goes undiag-
nosed, and most authorities accept a somewhat higher
true prevalence of between 1 in 3,0008 and 1 in 5,000
people.9
Current medical therapy for Marfan syndrome consists
mainly of β-blocker therapy. This approach, suggested by
Halpern et al,10 was intended to reduce the rate of rise of
aortic pressure, dP/dt, to reduce the forces imposed upon
the aortic wall and so to reduce the rate of aortic dilation.
The randomized evidence supporting the use of
β-blockers is limited to a single, small, open-label trial.11
Many patients experience progressive aortic dilation
despite such therapy,12,13 and prophylactic aortic root
surgery is often required.
Remarkable progress has been made in recent years in
understanding the pathophysiological basis of Marfan
syndrome.14 Mutations in the FBN-1 gene, which encodes
the extracellular matrix protein, fibrillin-1, were identified
as the cause of Marfan syndrome in a number of families,15
and modern DNA sequencing techniques can now identify
FBN-1 mutations in up to 92% of patients.16
Data from mouse models suggest that many of the
manifestations of Marfan syndrome arise as a conse-
quence of dysregulated Transforming Growth Factor β
(TGFβ) signaling. The angiotensin receptor blocker
(ARB) losartan (which down-regulates TGFβ signaling)
rescued the aortic phenotype in a mouse model of Marfan
syndrome,17 suggesting that targeted manipulation of
TGFβ or its downstream pathways and regulators could
prove to be productive strategies for the prevention of
aortic disease in Marfan syndrome in patients.18-29
Several observational studies of ARBs in patients with
Marfan syndrome have shown promising reductions in
the rate of aortic dilation, both in combination with
β-blockers12,30 and as monotherapy.31 Furthermore, 2
relatively small, randomized studies found reduced rates
of aortic dilation in patients with Marfan syndrome
(already taking β-blockers in most or all cases), randomly
allocated to losartan, compared to patients who were
randomly allocated to open-label control.23,27
Rationale for a meta-analysis of ARB trials in Marfan
syndrome
Ten randomized controlled trials of ARBs in patients
with Marfan syndrome were in progress at the time of
protocol writing, each designed to evaluate the effects of
ARBs, compared to either β-blockade or placebo/open-
label control, on aortic root size (and other aspects of
cardiovascular and noncardiovascular structure and
function).18-29 These studies plan to answer a number
of important questions regarding the efficacy, safety, and
tolerability of ARB therapy in different circumstances.
Individually, however, some of these studies may not be
large enough to answer reliably a number of important
outstanding questions regarding the effects of ARB
therapy in Marfan syndrome.
Meta-analyses of randomized trials can, by reducing
random errors and tending to minimize biases, provide
more reliable estimates of the effects of a particular
treatment strategy than any individual study.32 If individ-
ual participant data from these trials of ARBs in Marfan
syndrome were to be combined, a meta-analysis of the
resulting data (from approximately 2,300 patients) would
provide more precise estimates across a number of trials
of the treatment effects both of ARB therapy and
β-blockade. In particular, it will increase statistical
power to address the question of whether the treatments
studied influence a clinically important composite end
point of several clinical outcomes.
A meta-analysis of all trials will—because of its large
size—allow sources of variation in the effect of treatment
(eg, by age, baseline aortic root dimensions, or genotype)
to be explored. Finally, a meta-analysis may be able to
explore subsidiary hypotheses about the effects of
treatments on a range of outcomes of interest beyond
aortic root dimensions.
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The principal investigators of these trials were contacted
in 2012 and were asked if they might be willing to join a
collaborative group—the Marfan Treatment Trialists' Col-
laboration (MTTC)—in which it would be prospectively
agreed that individual patient data from each trial would,
after the completion of each trial, be provided to a central
repository to allow for an individual patient data meta-
analysis to be performed.
A prospective study design, in which the principal
hypotheses, trial eligibility criteria, analyses, and methods
are specified in advance of the unblinding of the
component trials, will help to limit bias owing to
data-dependent emphasis on the results of particular trials.
Members of the MTTC attended a series of meetings in
Chicago in July 2012 and in Munich in August 2012 and
subsequently agreed a protocol for such a meta-analysis in
late 2012. Since the protocol was finalized, the results
from 2 open-label trials have been published,23,27 and the
results of the remaining trials are awaited.
This report summarizes the protocol and statistical
analysis plan, which together define the rationale, trial
eligibility criteria, analyses to be performed, and statisti-
cal methods that were agreed upon by members of the
MTTC, without foreknowledge of the results of the
component trials. The full protocol and detailed statistical
analysis plan will be made available online (http://www.
ctsu.ox.ac.uk/research/meta-trials).
Aims
Primary aim
The primary aim of this meta-analysis is to estimate the
effect of (i) ARB therapy and (ii) β-blocker therapy, on
change in aortic root size across a number of trials
conducted in patients with Marfan syndrome and no
prior aortic root surgery.
Secondary aims
The secondary aims of this meta-analysis are to assess
the effects of these 2 treatment modalities on:
1. change in aortic root size at the sinuses of Valsalva
among different patient subgroups, defined on the
basis of baseline characteristics (Table II);
2. cardiovascular outcomes, including a composite of
aortic dissection, aortic root surgery, or death, and on
individual components of this endpoint (Table III); and
3. clinically or biologically important secondary out-
comes of interest (Table III).
Methods
Study eligibility and identification
Randomized trials in patients with Marfan syndrome
(defined according to the 1996 Ghent criteria33 or the
updated 2010 Ghent criteria34) are eligible for inclusion
in the meta-analysis if they include a properly randomized
comparison of one or both of (i) ARB versus placebo (or
open-label control) or (ii) ARB versus β-blockers.
The inclusion of trials that have allocated patients to
ARB versus placebo (or open-label control) and those that
have allocated patients to ARB versus β-blockers allows
not only for unbiased assessments of treatment effects of
ARBs but also, indirectly, for an assessment of the effect
of β-blockers versus placebo or open-label control.
Relevant trials were identified by searching online trial
registries (eg, clinicaltrials.gov, ISRCTN, PUBMED); compu-
ter-aided and manual searches of journals; scrutiny of
published trial protocols, abstracts and meeting proceed-
ings, and the reference lists of review articles; and inquiry
among colleagues, collaborating trialists, and manufacturers
of ARBs. These sources will be rechecked periodically to
identify trials that may be relevant but were not registered at
the time of protocol drafting. The list of the trials currently
identified as being eligible is shown in Table I.
Analytic approach
The primary analytic approach for the meta-analysis will
be according to the intention-to-treat principle, classifying
each randomized subject according to their assigned
treatment. Where participants discontinue allocated treat-
ment strategies after randomization, data from such
participants will continue to be included where available.
Primary analysis
Primary outcome. The primary outcome will be the
annual rate of change of body surface area (BSA)–adjusted
aortic root dimension z-score, measured at the aortic
sinuses of Valsalva. The z-score is a dimensionless quantity,
representing the signed number of standard deviations
(SDs) away from the mean where an observation lies.
For the primary analysis, data from subjects with prior
aortic root surgery at enrollment (enrolled in only a
minority of trials) will be excluded. For subjects who
underwent aortic root surgery or who died during the
follow-up period, measurements of aortic root dimensions
obtained before aortic surgery or death will be included in
the analysis. Measurements of aortic root dimensions
obtained after aortic root surgery will not be included.
For each trial, the imaging method of estimating aortic
root dimension used for that trial's primary analysis will be
used as the primary outcomemeasure in this meta-analysis.
Aortic root dimensions will be scaled for body size and
normalized to appropriate reference populations. For each
patient, linear slopes of rate of change of BSA-adjusted
aortic root dimension z-score will be calculated.
Sources of variation in the method of aortic root
measurement (including, for example, leading-edge to
leading-edge method, compared to inner-edge to inner-
edge method; systolic compared to diastolic measures)
and in the methods used for body size indexation and
reference population normalization will be explored and
reported (see Secondary outcomes below).
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Table I. Register of all current and planned randomized trials of angiotensin receptor antagonists in Marfan syndrome
Study
Sample
size
Diagnostic
criteria
Aortic size
criteria
Age (y)
Treatment Comparator
Follow-up
duration
(mo)
Primary end
point
Timing of
follow-up
visits (mo)
Imaging
methods
Study
end
date
ARB vs β-blocker
US (Pediatric
Heart
Network)
608 Ghent z-score
N3.0 and
aortic root
≤5.0 cm
0.5-25 Losartan 0.4-
1.4 mg/kg daily
Atenolol 36 Rate of change in aortic
root (sinus of Valsalva)
BSA-adjusted z-score
6, 12, 24, 36 Echo Nov
14
Italy (ARB vs β-
blocker arms)
156 Ghent and mutation
in FBN1
z-score ≥2
or aortic
root N3.8 cm
(F)/N4.0 cm
(M) and
b5.0 cm
1-55 Losartan target
dose 100 mg daily
Nebivolol 48 Aortic root growth rate 12, 24, 36, 48 Echo Sept
15
Spain 150 Ghent No minimum,
aortic root
≤4.5 cm
5-60 Losartan 12.5-
100 mg daily
Atenolol 36 Progression of aortic dilation 6, 12, 24, 36 CMR Sept
14
US (Boston) 50 Ghent Unrestricted 25+ Losartan Atenolol 6 Arterial stiffness measures 6 Echo Sept
14
Canada 17 Ghent Unrestricted 12-25 Losartan Atenolol 12 Pulse wave velocity 12 Echo Sept
14
ARB vs placebo (or open-label control)
UK 490 Revised Ghent z-score N0,
aortic root
b4.5 cm
≥6-40 Irbesartan 150-
300 mg daily⁎
Placebo⁎ 48-60 Absolute change in aortic
root diameter per year
12, 24, 36,
48, 60
Echo Sept
18
The Netherlands 233 Ghent No minimum
size, but
aortic root
b5 cm
≥18 Losartan 50-
100 mg daily⁎
Open-label
control⁎
36 Largest change at any aortic
level by MRI from baseline
to end of study
12, 24, 36 CMR (0 and 36) Nov
13
France 300 Ghent Unrestricted ≥10 Losartan 50-
100 mg daily⁎
Placebo⁎ 36 Rate of change of normalized
aortic root diameter expressed
as z-score
6, 12, 18,
24, 30, 36
Echo Sept
14
Italy (ARB + β-
blocker vs β-
blocker arms)
156 Ghent and mutation
in FBN1
z-score ≥2
or aortic root
N3.8 cm
(F)/N4.0 cm
(M) and
b5.0 cm
1-55 Losartan 100 mg
and nebivolol
Nebivolol 48 Aortic root growth rate 12, 24, 36, 48 Echo Sept
15
Belgium 39 Revised Ghent z-score ≥2.0 ≥10 Losartan 25-
100 mg daily⁎
Placebo⁎ 36 Rate of change in the aortic root
by linear regression of the z-score
6, 12, 24, 36 Echo (primary) and
CMR (0 and 36)
Dec
14
Taiwan 29 Ghent Recognized
aortic dilation
1+ Losartan and
either atenolol
or propranolol
Atenolol or
propranolol
35 Aortic root growth rate 35 Echo Mar
13
Imaging methods: where N1 imaging method is listed (primary) indicates the method used for the primary outcome. Abbreviations: MRI, magnetic resonance imaging; CMR, cardiovascular magnetic resonance
⁎ Trials based in the UK, France, Belgium, and theNetherlands allow enrolled patients to remain on their baseline therapy (usually, but not always β-blockers). The Italian and Taiwanese trials mandate β-blocker in the comparator arm(s). The Italian trial is
randomizing 235 subjects in a 3-way, 1:1:1 randomization, to losartan alone, nebivolol alone, or losartan + nebivolol. Sample per arm is estimated as 78 (235/3) and 156 per comparison (78 × 2).
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Effect of ARB versus placebo and of ARB versus β-
blocker on aortic root size. Between-trial variation in
age-range, other eligibility criteria, and treatment proto-
col, a common analysis plan will be implemented
separately within each participating trial. For each trial,
the difference in mean annual rate of change of
BSA-adjusted aortic root dimension z-score between
patients allocated to ARBs and patients allocated to
control therapy (ie, placebo/open-label control or
β-blocker, depending on the trial) will be estimated, as
will the standard error of this mean difference.
Standard inverse-variance–weighted methods for meta-
analysis will then be used to estimate (separately) the effect
on aortic root dimensionof allocation toARB versus placebo
(or open-label control) (in the 6 trials that provide such a
comparison) and the effect of allocation to ARB versus
β-blocker (in the 5 trials that provide such a comparison).
Results will be considered to be statistically significant if
the 2-sided P value is b.05, but chief emphasis will always
be placed on the effect size estimate and its associated
confidence intervals, which are the primary results of
meta-analyses.
Effect of β-blockers on aortic root size: combining
direct and indirect evidence. Only 1 of the 10 trials
identified allows for a direct randomized assessment to
be made of the effect of allocation to β-blockers
(compared with control) on aortic root dimension (the
Italian trial; Table I). However, an indirect assessment of
the effect ofβ-blockers on aortic root dimension (and some
other outcome measures) can be made from the other 9
trials, by combining the results from the 5 trials that only
compared ARB versus β-blockers with the results from the
4 trials that only compared ARB versus placebo (or
open-label control).
Specifically, if d1 (with variance v1) is the difference in
mean annual rate of change in aortic root dimension
estimated from the 5 trials that only compared ARB versus
β-blockers and d2 (with variance v2) is the difference in
mean annual rate of change in aortic root dimension
estimated from the 4 trials that only compared ARB versus
placebo/open control, then an indirect estimate of the
effect of β-blockers is provided by d2− d1 (which has
variance equal to v1 + v2).
The overall estimate of the effect on aortic root
dimension of allocation to β-blocker is then provided
by the inverse-variance–weighted average of the direct
result from the Italian trial and the indirect evidence from
the 9 other trials.35
For the comparison of ARB versus placebo, the random-
ization of N1200 patients should provide N90% power (with
a 2-sidedα = .05) to detect a 0.2-SD difference in annual rate
of change of BSA-adjusted aortic root dimension z-score,
whereas the randomization of N900 patients to ARB
versus β-blocker would provide N80% power (with a
2-sided α = .05) to detect a between-group difference of 0.2
SD and N90% power to detect a 0.25-SD difference.
Secondary analyses
Subgroup analyses. The availability of individual
patient data will allow exploration of whether the benefits
or hazards of treatment with ARBs or β-blockers are
particularly great in certain types of patient, defined on the
basis of characteristics present at the time of
randomization.
The absolute effects on the primary outcome of allocation
to ARBs (and, indirectly, of allocation to β-blockers) versus
control will, therefore, be examined separately, according
to a limited number of subgroups defined by prespecified
baseline characteristics (Table II).
Tests for differences in the absolute treatment effect
according to each characteristic (ie, tests for interaction)
will be derived from standard tests for heterogeneity/
trend across subgroups or, where needed, by fitting
appropriate interaction terms with treatment allocation
in a linear regression model.
Because the likelihood of a false-positive result (ie, a type
I error) increases with the number of subgroup analyses
performed, these tests will not be considered statistically
significant unless the interaction P value is b.01 (and, even
then, may be considered only as “hypothesis-generating”).
Secondary analyses will always be identified as such in
manuscripts arising from this work.
Some baseline characteristics (eg, sex, age at enrollment)
are expected to be available for all enrolled participants in all
trials. Other baseline characteristics (eg, markers of arterial
elasticity) may only be available from a subset of trials. In
these cases, analyseswill be performed on the available data,
where sufficient data are available for reliable and informa-
tive analysis. Analyses will be performed first on all trials
evaluating the ARB losartan and, subsequently, on all ARB
trials, irrespective of the ARB used.
Although data from subjects with a history of aortic root
surgery at enrollment (enrolled in only a minority of trials)
will be excluded from the primary analysis, a secondary
analysis will be performed using data exclusively from
those subjects who gave a history of aortic root surgery at
baseline. For this analysis, absolute ascending aortic root
dimensionswill be themain outcome of interest, and aortic
arch dimensions and descending aortic dimensions will be
considered to be the principal secondary outcome
measures for this analysis.
For each trial, wewill report the proportion of subjects in
whom genetic testing has been performed, the proportion
of subjects inwhommutations have been identified, and the
loci affected. Subgroup analyses will be performed based on
presence or absence of mutations at particular loci (eg,
FBN-1 mutations) and, where possible, based on the
predicted functional consequence of particular categories
of mutation (eg, nonsense vs missense FBN-1 mutations)
among those subjects with identified mutations.
Circulating biomarkers of vascular function (eg, TGFβ;
matrix metalloproteinases; and their circulating regulators,
fibrillin-1 fragments) or samples suitable for analyses of these
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and other biomarkers may be available from some trials.
Analyses of these biomarkers may be feasible, but such
analyseswill only be considered to behypothesis generating.
Secondary outcomes. Analyses will be performed to
estimate the effect of ARB therapy (and, indirectly, of
β-blockers) versus control on certain prespecified
secondary outcome measures (Table III).
Continuous measures will be analyzed by calculating the
inverse-variance–weighted average result across the trials
(using, when appropriate, repeated-measures methods for
each trial). Time-to-event outcomes will be analyzed using
log-rank methods for meta-analyses. All P values will be 2
sided, with a significance level of .05 being deemed
significant, but any marginally significant results will be
interpreted with appropriate caution and may be consid-
ered only as hypothesis generating.
Differences in the proportional effects of allocation to
ARB (and, indirectly, of allocation to β-blocker) on the
prespecified secondary outcomes by baseline character-
istics (Table II) will also be assessed.
A sensitivity analysis will also estimate the effects of
different methods of BSA estimation, body size estimation
(height, BSA, BSA0.5), and normalization on the primary
outcome and on secondary outcomes where appropriate.
Exploratory analyses will be conducted to assess the
sensitivity of the final results to the analysis method used.
In particular, the effect size estimates for each of the
outcomes will be compared to those yielded by
“random-effects” models, and if these are substantially
discrepant, the final report will include a discussion of
possible reasons for any differences.
Interim analyses
The final analysis will seek to include all trials of ARBs
worldwide. Interim analyses may be performed if ≥1
trials are delayed, and these analyses may be submitted
for publication before the completion of all trials. A
separate analysis, confined to those trials evaluating the
ARB losartan, will be performed before an analysis of
trials including all ARBs.
Collaborative group structure, organization, and
management
The meta-analysis will be undertaken by the MTTC,
which is a collaborative group of trialists, meta-analysts,
statisticians, biological scientists, and clinicians. The group
includes representatives of each collaborating trial and
meets periodically to discuss the design, conduct, and
reporting of this meta-analysis. The study is supported and
coordinated by a secretariat based at the Clinical Trial
Service Unit & Epidemiological Studies Unit, University of
Oxford, UK, and at the Division of Cardiovascular
Medicine, Radcliffe Department of Medicine, University
of Oxford, UK.
Protocol preparation and publication policy
Draft versions of the protocol and statistical analysis plan
were prepared by the secretariat in spring 2012 and were
reviewed at the meetings of the MTTC in Chicago in July
2012 and in Munich in August 2012. Drafts were circulated
to all members of the collaboration throughout the process,
and the documents were finalized after a series of
teleconferences in late 2012.
Table II. Patient subgroup definitions based on characteristics at randomization
• Age at randomization⁎
• Sex
• Family history of aortic dissection in a first-degree family member (i) at any age and (ii) occurring in the family member at an age ≤40 y
• The presence or absence of:
▪ ectopia lentis
▪ dural ectasia
▪ musculoskeletal involvement†
• Aortic root dimension at the sinuses of Valsalva at enrollment, indexed to body surface area and expressed as a z-score‡
• Baseline age-adjusted imaging markers of arterial stiffness and elasticity
• Presence and type of variants in genes encoding components of the extracellular matrix including fibrillin-1; the TGFβ pathway; the renin-angiotensin
system; the β-adrenergic system; and pathways involved in the binding, transport, metabolism, or excretion of ARBs and/or β-blockers
• Circulating biomarkers of vascular function (including TGFβ level where available) at baseline
• Use of β-blockers at baseline
• Use of calcium-channel blockers at baseline
• Use of HMG CoA reductase inhibitors (statins) at baseline
• Prior history of aortic root surgery at baseline
• Systolic and diastolic blood pressure at baseline as a continuous measure§
⁎Both the linear dependence of the absolute treatment effect on age and the separate effect of treatment allocation among patients aged ≤16 years versus N16 years will be assessed.
†Defined as N4 major manifestations reaching a major criterion in the 1996 nosology.
‡As a continuous measure and categorized as b4.5 versus ≥4.5.
§As a continuous measure and categorized as b140 versus N140 systolic and b90 versus N90 diastolic.
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Manuscripts arising from the meta-analysis will be
prepared by the secretariat and reviewed by the
collaborative group. The main findings of the meta-
analysis will be submitted for publication in a peer-
reviewed journal irrespective of the outcome of the
overview. All publications will be submitted in the name
of the MTTC, listing all collaboration members. Further
information regarding the approach to analysis is
available on request from the corresponding author,
and inquiries from those wishing to perform similar types
of analyses would be particularly welcome.
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